Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Immunomedics New Blood Assay For PAM4-protein Detects Pancreatic Cancer

Immunomedics, a biopharma firm focused on developing monoclonal antibodies to treat cancer and other serious diseases, has reported that a new blood assay using the company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine.

Immunomedics had recently developed a new serum-based enzyme immunoassay (ELISA) for early diagnosis of pancreatic cancer, employing clivatuzumab that has a sensitivity of 62% for detecting stage-1 pancreatic cancer (disease confined to pancreas), 86% for stage 2 disease, and 91% for stage 3/4 (local and distant spread) cancers.

Immunomedics had reported an overall response rate of 68% with 5 patients having a partial response (PR), 10 with stable disease (SD) and 7 with progressive disease (POD). From the initial group of 22 patients, 17 were evaluable as having both baseline and follow-up sera available for PAM4 testing, of which 4 were PR, 11 patients with SD and 2 patients with POD. Notably, 1 patient was negative for PAM4 in the circulation and excluded from the evaluation.

The PAM4 ELISA correctly predicted 4 of 4 PRs. Four of 9 patients with SD were also predicted to have had a PR rather than an SD. However, it is noted that one of the SD patients had a 29% decrease in tumor size which is just under the 30% criteria under RECIST to qualify as a PR. Overall, the sensitivity for detection of a PR was 100% with a specificity of 68%. Importantly, neither of the patients with POD was falsely recognized as PR.

Separately, in a study to be reported later, the effects of adding an antibody-drug conjugate that targets pancreatic cancer (hRS7-SN-38) to Y-90 labeled Clivatuzumab tetraxetan were investigated in a mouse model of human pancreatic cancer. Results showed that the combination produced more robust objective response than each agent alone.

Immunomedics said that in particular, all animals receiving Y90-clivatuzumab at the maximum tolerated dose and hRS7-SN-38 achieved a tumor-free state within 4 weeks, while other animals continued to have evidence of persistent disease. These studies provide the first evidence that combined radioimmunotherapy and antibody-drug conjugate can enhance efficacy at safe doses.

Cynthia Sullivan, president and CEO, said: “We have now demonstrated that the blood assay for PAM4-protein can not only detect early-stage pancreatic cancer, as has recently been reported by us, but may also predict a lack of response to therapy or an early relapse. As a result, we believe we may be one step closer to offering an individualized approach for the management of this lethal disease.

“Although these results are based on a small number of patients, the trend encourages us to expand such studies to evaluate whether this new bioassay for pancreatic cancer continues to be predictive of response to diverse therapies.”